Atea Pharmaceuticals, Inc. Segments Disclosure
15. Segment Information
The Company operates as one operating segment, focused on discovering, developing and commercializing antiviral therapeutics. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s CODM. As CODM, the Company’s cr, uses consolidated, single-segment financial information for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods.
The CODM assesses performance and decides how to allocate resources based on consolidated net loss. This measure is used to monitor budget versus actual results to evaluate the performance of the segment.
The CODM reviews cash, cash equivalents and marketable securities as a measure of segment assets. As of December 31, 2025 and 2024, the Company’s cash, cash equivalents and marketable securities were $301,830 and $454,721, respectively.
The following table illustrates information about significant segment expenses and segment operating loss for the years ended December 31, 2025 and 2024:
Year Ended December 31, |
|
|||||||
|
|
2025 |
|
|
2024 |
|
||
Research and development expense (1) |
|
|
|
|
|
|
||
HCV external costs (2) |
|
$ |
109,574 |
|
|
$ |
34,106 |
|
COVID-19 external costs (2) |
|
|
1,490 |
|
|
|
60,734 |
|
Early stage discovery external costs (2) |
|
|
3,800 |
|
|
|
943 |
|
Compensation and related expenses |
|
|
18,753 |
|
|
|
20,448 |
|
Consulting and professional fees |
|
|
2,183 |
|
|
|
1,959 |
|
Other research and development expenses |
|
|
1,778 |
|
|
|
1,839 |
|
Total research and development expense |
|
|
137,578 |
|
|
|
120,029 |
|
General and administrative (3) |
|
|
|
|
|
|
||
Compensation and related expenses |
|
|
9,094 |
|
|
|
9,279 |
|
Consulting and professional fees |
|
|
12,004 |
|
|
|
10,031 |
|
Other general and administrative |
|
|
1,491 |
|
|
|
1,844 |
|
Total general and administrative |
|
|
22,589 |
|
|
|
21,154 |
|
Stock based compensation |
|
|
20,720 |
|
|
|
51,767 |
|
Other segment items (4) |
|
|
(22,538 |
) |
|
|
(24,564 |
) |
Net loss |
|
$ |
(158,349 |
) |
|
$ |
(168,386 |
) |
|
|
|
|
|
|
|
||
(1) Research and development expense for the years ended December 31, 2025 and 2024 excludes stock based compensation of $10,446 and $24,072, respectively.
(2) External costs consist primarily of discovery, preclinical, clinical and manufacturing related activities.
(3) General and administrative expense for the years ended December 31, 2025 and 2024 excludes stock based compensation of $10,274 and $27,695, respectively.
(4) Other segment items include Interest income and other, net and income tax benefit (expense).
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Mar 6, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.